97.63 USD
▼-3.83-3.77%
盘后 103.00 0.00%
2026-11-19
市值
$9.17B
市盈率
—
EPS
-2.73
股息率
—
52 周区间
23.01 – 110.64
成交量
628.95K
Beta
3.23
目标价
123.87
52W 低 23.0152W 高 110.64
价格走势
公司简介
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo...